Psilocybin is under clinical development by Compass Pathways and currently in Phase II for Major Depressive Disorder. According to GlobalData, Phase II drugs for Major Depressive Disorder have a 39% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Psilocybin’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Psilocybin is under development for the treatment of treatment-resistant depressive disorder (P-TRD), autism, major depressive disorder, anorexia nervosa and body dysmorphic disorder. It is formulated as the capsule and administered by oral route. The drug candidate is a tryptamine alkaloid which is a psychedelic prodrug compound acts by targeting 5hydroxy tryptamine 1A and 2A.
Compass Pathways overview
Compass Pathways (CMPS) is a mental health care company that focuses on enhancing the lives of people suffering with mental health challenges and who do not respond to existing treatments. It is investigating a novel therapy based on its proprietary formulation of synthetic psilocybin, COMP360 in phase IIb clinical studies. The COMP360 holds Breakthrough Therapy designation from the the US Food and Drug Administration (FDA) for treatment-resistant depression (TRD) in combination with psychological support. The company operates offices in New York, the US. CMPS is headquartered in Altrincham, Cheshire, the United Kingdom.
For a complete picture of Psilocybin’s drug-specific PTSR and LoA scores, buy the report here.